FDA Strains Under New NDA Review Model; Will Industry Want To Retain It?
Executive Summary
Scheduling mid- and late-cycle meetings complicates reviews for FDA, but the fate of the “Program” probably depends on whether industry feels the extra two months produces better outcomes.
You may also be interested in...
Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.
Alexander Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.
Senator Tells FDA To Create ‘Red Team’ For Regulatory Streamlining
HELP Committee Chairman Lamar Alexander wants FDA to suggest regs and other bureaucratic requirements that are hindering productivity as part of medical innovation effort.